Thyrocare Technologies Limited has fixed Tuesday, June 23, 2026, as the record date to determine shareholder eligibility for the final dividend of ₹7.00 per equity share for FY26. The payment, subject to approval at the 26th Annual General Meeting (AGM) scheduled for June 30, 2026, will be made on or before Wednesday, July 29, 2026. The Board recommended this dividend at its meeting on May 7, 2026.

The company has submitted its Annual Report for FY 2025-26 to the stock exchanges under Regulation 30 and 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The AGM will be held at the company's Corporate Office in Navi Mumbai.

Financial Performance

Thyrocare delivered robust financial results for FY 2025-26, with significant year-on-year improvement. The table below summarises the audited financial performance:

On a consolidated basis, EBITDA margin stood at 31.03% in FY 2025-26 versus 27.49% in FY 2024-25, while Return on Capital Employed (ROCE) improved to 33.87% from 25.97%.

Segment-wise Performance

Pathology remained the primary revenue driver, contributing approximately 94% of consolidated revenue. The Jaanch platform recorded a twofold increase in sales during the year.

Key Operational Highlights

During FY 2025-26, the company added 7 new laboratories, taking the total to 41 labs. It became India's first diagnostic chain to achieve 100% NABL accreditation across all laboratories. Tests conducted reached 209.6 million in FY 2026 versus 170.5 million in FY 2025.

Dividend and Capital Structure

The total dividend for FY 2025-26 aggregates to ₹9.33 per equity share (post bonus adjustment), including an interim dividend of ₹2.33 per share already paid. The company completed a bonus issue in the ratio of 2:1 during the year.

Thyrocare Technologies Limited has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26 to the National Stock Exchange of India Limited and BSE Limited. The disclosure, made on June 04, 2026, details the company's adherence to the National Guidelines on Responsible Business Conduct (NGRBCs) and its Environmental, Social, and Governance (ESG) initiatives. The report serves as a comprehensive account of the company's sustainable practices and governance framework during the fiscal year.

The report highlights that the company generated a turnover of ₹ 774.27 Crore and recorded a net worth of ₹ 560.68 Crore. Thyrocare's operations are primarily concentrated in the diagnostic and healthcare sector, which accounted for 98.66% of its total turnover. The company operates 40 plants and 1 office nationally, alongside one international subsidiary, Thyrocare Laboratories (Tanzania) Limited.

Environmental Performance

Thyrocare reported a total energy consumption of 2272.07 Giga Joules for FY26, with an energy intensity of 42.56 GJ per crore rupees of turnover. The company has implemented initiatives to reduce its carbon footprint, including the installation of solar panels at its corporate office and two laboratory facilities. Water consumption stood at 18295 kilolitres, while water discharge was recorded at 730 kilolitres.

In terms of waste management, the company generated a total of 290.80 metric tonnes of waste, comprising 46.603 metric tonnes of plastic waste and 244.198 metric tonnes of bio-medical waste. The company ensures compliance with the Bio-Medical Waste Management Rules, 2016, through authorised vendors for disposal.

Social and Governance Metrics

The company employed a total of 2,092 employees as of March 31, 2026. Women constituted 26.67% of the total workforce. Thyrocare reported zero instances of fines, penalties, or legal proceedings against the entity or its directors and Key Managerial Personnel (KMPs) during the financial year.

The Board of Directors comprises nine members, with two women directors representing 22.22% of the Board. The company has established various policies, including the Anti-Bribery and Anti-Corruption Policy and the Whistle Blower Policy, to ensure ethical conduct and transparency.

Stakeholder Grievances

During FY26, the company received 7,389 complaints from customers, of which 17 were pending resolution at the end of the year. Employee grievances numbered 1,180, with all resolved. Shareholder grievances stood at two, with zero pending. The company maintains dedicated grievance redressal mechanisms for investors, shareholders, employees, and customers through its website and internal portals.